A recent EUSTAR cohort study evaluates the effectiveness of oral anticoagulants in treating precapillary pulmonary hypertension linked to systemic sclerosis. The findings contribute to understanding treatment options for this rare condition.

A new study provides an updated etiological and clinical classification of pulmonary hypertension in children, enhancing understanding of this complex condition. This classification aims to improve diagnosis and treatment strategies for affected pediatric patients.

A new study explores the link between pulmonary hypertension and various genetic syndromes, expanding the understanding of this complex disease. The findings may inform future research and treatment strategies for patients with pulmonary hypertension associated with genetic conditions.

Roivant reports positive results from the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study highlights the drug's potential in addressing significant unmet medical needs in this progressive condition.

David Ross continues to advocate for rare diseases, particularly pulmonary hypertension associated with interstitial lung disease (PH-ILD), two decades after losing his loved one. His advocacy highlights the ongoing need for compassion and dedication in supporting patients facing these challenges.